Drug
Bilastine clinical trials
- studies test it
- 22
- open now
- 0
- in phase 3
- 9
- first study started
- 2003
How studies write it
Studies that test it under each name
Studies by the year they started
22 studies that test it; most in 2006 (3)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 3 |
| 2010 | 3 |
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 6
- Phase 3
- 9
- Phase 4
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 18 · Other 4
Faes Farma, S.A. (14) · Menarini International Operations Luxembourg SA (2) · Charite University, Berlin, Germany (2) · Universidade do Sul de Santa Catarina (1) · Yuhan Corporation (1) · Grupo de Alergología Clínica y Experimental (1) · A.Menarini Asia-Pacific Holdings Pte Ltd (1)
Often tested with
Tested in the same studies.
Montelukast (1) · Loratadine (1) · Cetirizine (1) · Desloratadine (1) · Fexofenadine (1) · Ebastine (1)
Studies
Open first, then newest update. How each study uses bilastine is read from its arms, and is right about nine times in ten.
Testing it · 22
- A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® ModelCompletedPhase 2Faes Farma, S.A.NCT03231969Written as Bilastine 0.2%
- Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in ChildrenCompletedPhase 3Faes Farma, S.A.NCT04810390Written as Bilastine
- A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.CompletedPhase 3Faes Farma, S.A.NCT03479307Written as Bilastine Ophthalmic Solution 0.6%
- Efficacy of Co-administration of Bilastine and Montelukast in Patients With SARC and AsthmaCompletedPhase 4Menarini International Operations Luxembourg SANCT02761252Written as Bilastine 20mg
- PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm)CompletedPhase 2Faes Farma, S.A.NCT00574210Written as Bilastine
- Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SARCompletedPhase 2Faes Farma, S.A.NCT00574379Written as Bilastine
- Different Level of Single-dose and Multiple-dose Bilastine PK Study in Chinese PopulationStatus unknownPhase 1A.Menarini Asia-Pacific Holdings Pte LtdNCT03633760Written as Bilastine 40mg single dose
- Quality of Life in Patients With Allergic Rhinitis: Clinical Trial With Bilastine or LoratadineCompletedPhase 4Universidade do Sul de Santa CatarinaNCT02513290Written as Bilastine
- Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or UrticariaCompletedPhase 4Menarini International Operations Luxembourg SANCT02576041Written as Bilastine
- Bilastine Updosing in Chronic Spontaneous UrticariaCompletedPhase 3Charite University, Berlin, GermanyNCT02213367Written as Bilastine
- Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg in Korean Patients With Seasonal Allergic RhinitisCompletedPhase 3Yuhan CorporationNCT01400828Written as Bilastine
- Evaluation of the Inhibitory Effect of 5 Anti-Histamines in UrticariaCompletedPhase 4Grupo de Alergología Clínica y ExperimentalNCT01940393Written as Bilastine
- Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU)CompletedPhase 1/2Faes Farma, S.A.NCT01081574Written as Bilastine
- Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety ExtensionCompletedPhase 3Faes Farma, S.A.NCT01127620Written as Bilastine
- Oral Bioavailability of BilastineCompletedPhase 1Faes Farma, S.A.NCT01124123Written as Bilastine
- Human Mass Balance Study With BilastineCompletedPhase 1Faes Farma, S.A.NCT00572611Written as [14C]-bilastine
- Bilastine Updosing - Characterization of Underlying MechanismsCompletedPhase 2/3Charite University, Berlin, GermanyNCT01271075Written as Bilastine
- A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge ChamberCompletedPhase 2Faes Farma, S.A.NCT00420082Written as Bilastine
- Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic UrticariaCompletedPhase 3Faes Farma, S.A.NCT00421109Written as Bilastine
- Efficacy Study for the Symptomatic Treatment of Seasonal Allergic RhinitisCompletedPhase 3Faes Farma, S.A.NCT00504933Written as bilastine
See all 22 studies that test bilastine →
Given in every arm · 1 — bilastine is usual care beside what is tested
As the comparator · 1 — what is tested is compared with bilastine
Codes
What other systems call bilastine · ClinicalTrials.gg INT004413
- MeSH (NLM) C445659bilastineOne source NLM
- UNII (FDA) PA1123N395BILASTINEConfirmed FDA, NLM, Wikidata
- Wikidata Q2902977bilastineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C73045BilastineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C445659 | bilastine | One source NLM |
| UNII (FDA) | PA1123N395 | BILASTINE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q2902977 | bilastine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C73045 | Bilastine | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.